ACETAMINOPHEN INJECTION SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Osta kohe

Toote omadused Toote omadused (SPC)
24-02-2023

Toimeaine:

ACETAMINOPHEN

Saadav alates:

B. BRAUN MELSUNGEN AG

ATC kood:

N02BE01

INN (Rahvusvaheline Nimetus):

ACETAMINOPHEN (PARACETAMOL)

Annus:

100MG

Ravimvorm:

SOLUTION

Koostis:

ACETAMINOPHEN 100MG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

15G/50G

Retsepti tüüp:

Prescription

Toote kokkuvõte:

Active ingredient group (AIG) number: 0102009015; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2023-02-24

Toote omadused

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACETAMINOPHEN INJECTION
Acetaminophen Injection
Sterile solution for infusion, 10 mg/mL, intravenous
(Available as 100 mg/10 mL, 500 mg/50 mL and 1000 mg/100 mL)
Analgesic and Antipyretic
B. BRAUN MELSUNGEN AG
Carl-Braun-Strasse 1
34212 Melsungen, Germany
Date of Initial Authorization:
February 24, 2023
Imported and Distributed by:
B. BRAUN OF CANADA, LTD.
2000 Ellesmere Road, Unit 16
Scarborough, Ontario M1H 2W4
Submission Control No: 244695
Acetaminophen Injection
Page 2 of 26
RECENT MAJOR LABEL CHANGES
None at time of authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................... 4
1
INDICATIONS
......................................................................................................................
4
1.1
Pediatrics.......................................................................................................................
4
1.2
Geriatrics
.......................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
......................................................................................
5
4.1
Dosing Considerations
...................................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment................................................
                                
                                Lugege kogu dokumenti
                                
                            

Otsige selle tootega seotud teateid